Key Highlights

  • The FDA issued a Not Substantially Equivalent determination on the EchoSolv HF 510(k) application, as referenced in an ASX announcement of 8 September 2026.
  • The company is assessing an administrative appeal, FDA Ombudsman review or a new 510(k) submission.
  • The company states there has been no material impact to its strategic partner agreements.

Echoiq Ltd (ASX:EIQ) shares were priced at $0.423 during the trading session on 19 October 2026, down 1.74%. Echoiq is an AI and medical technology company that develops software for clinical decision-making in cardiology. On 17 September 2026, the company released an update on its EchoSolv HF 510(k) application with the US Food and Drug Administration (FDA), following an earlier ASX announcement on 8 September 2026. The price data relates only to the 19 October 2026 session and is separate from the release date.

The FDA determination

The update follows receipt of a Not Substantially Equivalent (NSE) determination from the FDA on the initial EchoSolv HF 510(k) application. The company states that it is working with regulatory consultants and legal counsel to advance clearance and is committed to working with the FDA to address all matters cited.

According to the company's review, the matters cited relate to aspects of the statistical analysis supporting clinical validation, and its assessment did not identify concerns about the underlying technology or the core functionality of the device. Echoiq says it believes clearance remains achievable under the 510(k) route and that clearance could potentially be achieved over the coming quarters.

Pathways under assessment

The company is considering three pathways: an administrative appeal of the NSE determination, review through the FDA Ombudsman, or a new 510(k) submission. It states that an administrative appeal would allow it to challenge the FDA's scientific and regulatory conclusions and obtain context on the FDA's rationale, and that timelines are not strictly defined and in certain circumstances may be shorter than 90 days.

If an appeal is filed, the company lists possible outcomes: the NSE determination being overturned, the FDA reopening its review and potentially providing clearance, or the FDA requesting resubmission of a 510(k). The FDA Ombudsman route may assist with a procedural review, and a 510(k) resubmission can be undertaken over the coming quarters.

Partner agreements and product background

The company states that there has been no material impact to its strategic partner agreements, including those with Advara HeartCare, Mayo Clinic and Pro Medicus Limited. Its flagship product EchoSolv AS is FDA-cleared as a clinical decision support aid in the detection of severe aortic stenosis. Echoiq is headquartered in Sydney with US operations in Greenville, Delaware.

Context for the regulatory update

The update refers back to an ASX announcement of 8 September 2026 in which the company disclosed the FDA's determination. The company says its position is that the issues relate to statistical analysis supporting clinical validation. It also states that it is working with regulatory consultants and legal counsel and will continue to assess pathways, and that a resubmission process can be undertaken over the coming quarters.

Sector backdrop

Medical software that supports clinical decisions in the United States generally requires FDA clearance, commonly through the 510(k) pathway, which assesses whether a device is substantially equivalent to an existing one. Clearance timelines can vary and often involve additional data requests or resubmissions. Reimbursement frameworks, such as the CMS payment proposals referenced in the company's forward-looking statements, also affect commercial pathways for AI-based diagnostic tools.

Risks shareholders should weigh

The press release and the wider operating environment point to several considerations that shareholders may wish to weigh:

  • The company states that a revised or new submission to the FDA may not be made or may not succeed, and that clearance may not be obtained within any particular timeframe, or at all.
  • Commercial plans for EchoSolv HF remain subject to obtaining the required regulatory clearances.
  • The forward-looking statements refer to a further A$10 million investment tranche from Pro Medicus Limited that is conditional on FDA clearance of EchoSolv HF.
  • The company's reimbursement outlook refers to CMS proposed rules that have not been finalised.
  • Timelines for an administrative appeal, an Ombudsman review or a new submission are described as not strictly defined.

What's next

The company says it will keep investors and shareholders informed of progress on obtaining clearance for EchoSolv HF. Next steps listed are to continue addressing the matters cited by the FDA, to decide between an administrative appeal, an Ombudsman approach or a new 510(k) submission, and to work with regulatory advisors and counsel. The company believes clearance could potentially be achieved over the coming quarters.